News

Captor Therapeutics announces further robust in-vivo efficacy data from CT-01 TPD candidates for hepatocellular carcinoma

Captor Therapeutics announces molecular targets of CT-01 program developing TPD therapy for hepatocellular carcinoma

Captor Therapeutics invited to TPD panel at the 8th Annual LSX World Congress 2022

Captor Therapeutics named as the most innovative company on the WSE in the Stock Exchange Company of the Year ranking

Captor Therapeutics to Present at the 2nd Annual Targeted Protein Degradation Europe Summit 2022

Captor Therapeutics announces positive proof-of-concept efficacy in-vivo data for its lead CT-03 program with strong antitumor activity at all doses tested

Captor Therapeutics opens State-of-the-Art Proteomics Lab

Captor Therapeutics strengthens its scientific team and prepares for the launch of clinical trials in 2023 with the appointment of Dr. Robert Dyjas as Director of Medical Affairs and Clinical Development